Company Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme.
The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors.
The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
| Country | United States |
| IPO Date | Sep 25, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 128 |
| CEO | Dr. Krishna Vaddi D.V.M., Ph.D. |
Contact Details
Address: 200 Powder Mill Road Wilmington, Delaware United States | |
| Website | https://www.preludetx.com |
Stock Details
| Ticker Symbol | PRLD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001678660 |
| CUSIP Number | 74065P101 |
| ISIN Number | US74065P1012 |
| Employer ID | 81-1384762 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Krishna Vaddi D.V.M., Ph.D. | Founder, Chief Executive Officer & Director |
| Bryant David Lim J.D. | Interim Chief Financial Officer, Chief Legal Officer & Corporate Secretary |
| Michele Porreca M.B.A. | Chief People Officer |
| Aimee Crombie Ph.D. | Senior Vice President and Head of Strategic Planning & Operations |
| Dr. Andrew P. Combs Ph.D. | Executive Vice President & Chief Chemistry Officer |
| Dr. Edna Huang M.D. | President & Chief Medical Officer |
| Dr. Madhu Pudipeddi Ph.D. | Senior Vice President of Technical Operations |
| Dr. Peggy A. Scherle Ph.D. | Chief Scientific Officer |
| Lindsey Trickett | Vice President of Investor Relations |
| Naveen Babbar Ph.D. | Senior Vice President of Translation Medicine |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 8-K | Current Report |
| Nov 06, 2024 | 10-Q | Quarterly Report |
| Nov 06, 2024 | 8-K | Current Report |
| Oct 24, 2024 | 8-K | Current Report |
| Sep 13, 2024 | 8-K | Current Report |
| Sep 09, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Aug 12, 2024 | 8-K | Current Report |
| Jul 08, 2024 | 4 | Filing |
| Jun 18, 2024 | 4 | Filing |